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anti-tumor activity in low EGFR expressing HNSCC
cell lines and is effective in cells with acquired
resistance to cisplatin or cetuximab
Franziska Niehr1,2, Wilko Weichert3,4, Albrecht Stenzinger3, Volker Budach1,2 and Ingeborg Tinhofer1,2,5*Abstract
Background: The mammalian target of rapamycin (mTOR) signaling pathway plays a pivotal role in numerous
cellular processes involving growth, proliferation and survival. The purpose of this study was to investigate the
anti-tumoral effect of the mTOR inhibitor (mTORi) CCI-779 in HNSCC cell lines and its potency in cisplatin- and
cetuximab-resistant cells.
Methods: A panel of 10 HNSCC cell lines with differences in TP53 mutational status and basal cisplatin sensitivity
and two isogenic models of acquired resistance to cisplatin and cetuximab, respectively were studied. Cell
survival after treatment with CCI-779, cisplatin and cetuximab alone or in combination was determined by MTT
assays. Potential predictive biomarkers for tumor cell sensitivity to CCI-779 were evaluated.
Results: We observed considerable heterogeneity in sensitivity of HNSCC cell lines to CCI-779 monotherapy. Sensitivity
was observed in TP53 mutated as well as wild-type cell lines. Total and p-EGFR expression levels but not the basal
activity of the mTOR and MAPK signaling pathways were correlated with sensitivity to CCI-779. Resistant cells with
increased EGFR activation could be sensitized by the combination of CCI-779 with cetuximab. Interestingly, cell
lines with acquired resistance to cisplatin displayed a higher sensitivity to CCI-779 whereas cetuximab-resistant
cells were less sensitive to the drug, but could be sensitized to CCI-779 by EGFR blockade.
Conclusions: Activity of CCI-779 in HNSCC cells harboring TP53 mutations and displaying a phenotype of cisplatin
resistance suggests its clinical potential even in patients with dismal outcome after current standard treatment.
Cetuximab/mTORi combinations might be useful for treatment of tumors with high expression of EGFR/p-EGFR and/or
acquired cetuximab resistance. This combinatorial treatment modality needs further evaluation in future translational
and clinical studies.
Keywords: HNSCC, mTOR, EGFR, Temsirolimus, CCI-779, Cetuximab, Cisplatin, ResistanceBackground
Cancer of the head and neck region is the sixth most
common cause for cancer-related mortality worldwide
with 600,000 new cases and 300,000 deaths per year.
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unless otherwise stated.surgery, radiotherapy, and chemotherapy, alone or in com-
binations, have been used as therapeutic options over the
past decades. New treatment strategies such as epidermal
growth factor receptor (EGFR) inhibition by cetuximab
have been shown to prolong survival, but 5-year survival
rates of patients with locally advanced cancers are still at
50% or below [3]. Therefore, new therapeutic approaches
like second generation- or multi-target tyrosine kinase in-
hibitors, proteasome inhibitors, hypoxia-modifying agents,
or antiangiogenic agents have been or are being evaluated
in clinical trials [4-7]. Among these, one of the mosthis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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phatidylinositol 3-kinase-related kinase (PI3K) pathway,
since it represents the most frequently mutated oncogenic
pathway in HNSCC [8].
The mammalian target of rapamycin (mTOR) is a
serine/threonine protein kinase and belongs to the PI3K-
related kinase protein family. It is involved in many cellu-
lar processes like cell growth, proliferation, and survival
[9]. Different mTORi including rapamycin, RAD-001
(everolimus) and CCI-779 (cell cycle inhibitor-779, temsir-
olimus), but also dual mTOR inhibitors that target both of
the two mTOR complexes, mTORC1 and mTORC2 have
been evaluated [10,11]. In HNSCC, rapamycin [12,13],
everolimus [14] and temsirolimus [15], as well as dual in-
hibitors [16] have already shown promising effects in vitro
and in vivo. Their combination with irradiation, cisplatin
or reagents targeting the epidermal growth factor receptor
(EGFR) like cetuximab and erlotinib [17,18] has been
evaluated in preclinical models [11,19,20] and clinical
trials [21]. However, the molecular mechanisms of sensi-
tivity/resistance of HNSCC cells to mTORi remain poorly
characterized and no predictive biomarker for patient se-
lection has been established so far.Figure 1 CCI-779 shows an inhibitory effect on cell survival of cisplat
were treated with increasing doses of CCI-779 (0.1 to 1000 ng/ml). After 72
lines were treated with CCI-779 at 100 ng/ml for 7 days in long-term MTT ass
MTT assays (grey bars, right scale). Cells were then grouped in CCI-779-resistan
(A, B) Survival fractions for given treatments were calculated on the basis
and experiments were performed thrice.To evaluate the activity of the mTORi CCI-779 in
HNSCC in more detail and to identify predictive bio-
markers, the genetic profile, as well as mRNA- and protein
expression of genes involved in the mTOR pathway were
characterized in 10 HNSCC cell lines and correlated to
their sensitivity to CCI-779. Furthermore, the effectiveness
of CCI-779 in cells with primary/acquired resistance to
cisplatin and cetuximab was evaluated.
Results and discussion
Characterization of the growth-inhibitory potential in
HNSCC cell lines
In all tested HNSCC cell lines treatment with CCI-779
(100 ng/ml) for 72 h reduced cell viability, ranging from
a reduction of 69% in UM-SCC-11B cells down to 40%
in UT-SCC-15 cells compared to solvent-treated cells
(Figure 1 A). In long-term studies (7 days of treatment)
we were able to clearly distinguish sensitive from resist-
ant cells, with UT-SCC-23 representing the most resist-
ant (95% viability after treatment with 100 ng/ml) and
UM-SCC-25 (16% viability) the most sensitive cell line
(Figure 1 B). Of note, the IC50 of cisplatin, a widely used
radiosensitizer in HNSCC, only slightly differed betweenin-sensitive and -resistant HNSCC cell lines. (A) HNSCC cell lines
h cell survival was determined by the MTT assay. (B) The same cell
ays (black bars, left scale). Their IC50 for cisplatin was as well evaluated in
t (red) and -sensitive (green) lines using a cutoff of 50% cell survival.
of the survival of non-treated cells. Each sample was done in triplicate
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speaking against cross-resistance between the two drugs
(Figure 1 B). This finding together with the high efficiency
in most of the cell lines tested speaks for CCI-779 as po-
tentially effective therapeutic option in HNSCC cells with
primary resistance to cisplatin.
Neither TP53 status nor mutations in HNSCC-associated
oncogenic pathways predict sensitivity to CCI-779.
In search for predictive biomarkers for mTOR inhib-
ition the involvement of TP53 and other genes from
HNSCC-related oncogenic pathways for CCI-779 sensi-
tivity was determined. For this purpose, TP53 gene and
transcript sequences were analyzed by panel next-
generation sequencing (NGS) and Sanger sequencing,
respectively. In addition, the expression and functional
status of the p53 protein was determined. Sequencing
revealed distinct mutations of TP53 in the cell lines
tested, with Sanger sequencing and panel NGS giving
the same results (Tables 1 and 2). The cyclin-dependent
kinase inhibitor 1 (p21) represents one of the p53 tar-
gets. Its elevated expression after irradiation served as a
readout for functional activity of p53. There was no sig-
nificant correlation observed between the expression of
p53 transcripts (p = .988) or proteins (p = .990) or its
transcriptional function (p = .607) and the sensitivity of
cells to CCI-779 (Table 1). Previously, reduced sensitivity
of HNSCC cell lines carrying a TP53 mutation to a dual
PI3K/mTOR inhibitor was reported [22]. In line with
this previous study, wt TP53 was exclusively detected in
the group of sensitive cell lines, displaying decreased via-
bility after treatment with 100 ng/ml of temsirolimus
compared to mutated cells (mean viability ± SD: wt
TP53 group [N = 3], 0.36 ± 0.19 vs mutated TP53 group
[N = 7], 0.65 ± 0.27). However, this difference in viability
did not reach significance level (p = .139) which might
be due to the limited number of cell lines carrying wt
TP53 in our subset.Table 1 Characteristics of HNSCC cell lines
Cell line TP53 genotype p53 transcri
UT-SCC-23 Loss of transcript -
UM-SCC-11B missense mutation +
UD-SCC-5 missense mutation +
UD-SCC-4 delete, fs (stop codon) +
UM-SCC-22B missense mutation +
SCC-9 delete, fs +
UM-SCC-17B wt +
UM-SCC-74B wt +
UT-SCC-15 Incorrectly spliced transcript, fs +
UM-SCC-25 wt (+)
Cell lines were ordered by their resistance to CCI-779 at 100 ng/ml. Presented are t
assessed by measuring p21 and porphobilinogen deaminase (PBGD) mRNA expressPanel NGS revealed further mutations in key onco-
genic pathways including receptor tyrosine kinase, PI3K
or MAPK signaling in our cell lines (Table 2). Mutations
were also found in genes involved in cell cycle control
and cell death regulation, as well as in the tumor sup-
pressor SMAD4 and the transmembrane receptor gene
NOTCH1. None of these mutations was associated with
sensitivity to CCI-779. Since only one cell line within
our panel carried a PI3KCA mutation, the involvement
of this alteration in sensitivity to mTORi, as discussed in
other studies [8,22], could not be addressed.
CCI-779 sensitivity does not correlate with mTOR/MAPK
signaling pathway activity.
As potential biomarker for mTORi activity, the basal
activation of the mTOR or MAPK-pathway has been
discussed as well as the ability of mTORi to inhibit
downstream signaling of mTOR. It is thought that high
activity of the mTOR pathway renders tumor cells more
dependent on mTOR and results in higher sensitivity to
mTORi, whereas high activity of MAPK signaling has
been associated with reduced sensitivity to mTOR in-
hibition [8,23,24]. We therefore evaluated basal protein
expression levels of p-S6 (a downstream target of
mTOR) and p-Erk (a member of the MAPK pathway)
as well as their expression levels after mTOR inhibition
in four cell lines with highest and lowest sensitivity to
CCI-779 (Figure 2 A). No correlation could be found
between sensitivity of cells to CCI-779 and their basal
expression levels of p-S6 or p-Erk, with all cell lines
expressing phosphorylated, activated forms of these
kinases. Furthermore, CCI-779 was able to inhibit
phosphorylation of S6, downstream of p70S6K in all
tested cell lines regardless of their sensitivity to the
drug in the proliferation assays (Figure 2 A). To validate
these findings, we included all cell lines used in the
proliferation assays. Again, no correlation was found
between basal expression of total or activated proteinspt p53 protein function CCI-779 100 ng/ml
- - 95
+ - 87
+ - 81
- - 70
+ - 64
+ (trunc.) - 44
+ + 38
+ + 25
+ - 16
- - 16
heir TP53 genotype, transcript- and protein expression. P53 function was
ion before and after irradiation, using a cut-off of 1.5 fold induction.
Table 2 Mutations identified by panel next-generation sequencing for cell lines (upper panel) and resistance models (lower panel) used in this study
Cell line Cell cycle control TP53 Cell death regulation RTK signaling PI3K-akt signaling MAPK-signaling Others
UT-SCC-23 DEL SMAD4,FAT1
UM-SCC-11B Cys110Ser
UD-SCC-5 His47Tyr ERBB4, PDGFR FAT1, PCDH15
UD-SCC-4 DEL KDR, MYC FAT1, PCDH15
UM-SCC-22B Tyr88Cys CASP8 KIT NOTCH1, SMAD4, FAT1, PCDH15,
SCC-9 Val142fs KDR, RET FAT1, Notch1, PCDH15
UM-SCC-17B EGFR, KDR, KIT PIK3CA HRAS SMAD4, FAT1
UM-SCC-74B KDR, KRAS CDH1, FAT1, NOTCH1, PCDH15
UT-SCC-15 CDKN2A Arg282Trp CASP8 CDH1, FAT1
UM-SCC-25 CDKN2A ERBB4 SMAD4, FAT1
FaDuCDDP-S/R CDKN2A Arg248Leu 2% ➔ 47% SMAD4
UD-SCC-4CDDP-S/R DEL MYC, KDR 70% ➔ 100% FAT1, PCDH15, NSD1 0% ➔ 38%
UT-SCC-9CET-S/R CDKN2A DEL MET 35% ➔ 50% FAT1
UM-SCC-22BCET-S/R Tyr88Cys CASP8 KIT NOTCH1, SMAD4, FAT1, PCDH15
Mutations which affect protein function, as predicted by the SIFT [41] and PolyPhen [42] program are presented in bold, percentages of allele frequency are given if they differed between parental and resistant cells.
N
iehr
et
al.Journalof
TranslationalM
edicine
 (2015) 13:106 
Page
4
of
13
Figure 2 Resistance to CCI-779 is associated with high EGFR expression but does not correlate with reduced activity of CCI-779 in
blocking mTOR-signaling. (A) Two resistant (red, UT-SCC-23 and UM-SCC-11B) and two sensitive (green, UT-SCC-15 and UM-SCC-25) cell lines
were treated with 100 ng/ml CCI-779 for 24 h. The activation of the MAPK- (p-Erk) and mTOR- (p-S6) signaling pathways, as well as the expression
of the housekeeper protein GAPDH were evaluated using Western Blot. (B) All 10 cell lines were analyzed regarding their basal expression levels
of EGFR, p-Erk/Erk (MAPK pathway), and p-S6K/S6K (mTOR pathway) by Western Blot.
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CCI-779 (Figure 2 B).
HNSCC cells with primary resistance to CCI-779 display
high EGFR expression and can be sensitized by EGFR
blockade.
High EGFR protein and mRNA expression were de-
tected almost exclusively in resistant cells (Figures 2 B and
3 A). Interestingly, p-EGFR expression was elevated in the
group of cell lines with reduced sensitivity to CCI-779
(Figure 3B; mean p-EGFR expression ± SD: resistant group
[N = 5], 4.18 ± 1.97 vs sensitive group [N = 5], 1.78 ± 0.29).Statistical analysis revealed borderline significance (p =
0.052) for this association. Basal MAPK- (p-Erk) and
mTOR- (p-p70S6K) pathway activity did not differ be-
tween resistant and sensitive cells, therefore other
downstream targets of EGFR might be involved in resist-
ance to CCI-779. To test the hypothesis that overexpres-
sion of p-EGFR contributes to resistance to CCI-779,
three resistant cell lines, expressing high levels of EGFR
and p-EGFR, and three sensitive lines, expressing low
EGFR/p-EGFR levels, were treated with increasing con-
centrations of CCI-779 alone or in combination with a
Figure 3 Cell lines resistant to CCI-779 demonstrate higher
expression levels of EGFR mRNA and elevated p-EGFR protein
levels. (A) EGFR mRNA levels were measured by Real Time RT-PCR
and correlated to the housekeeper gene Tubulin alpha-6. The relative
EGFR mRNA expression was calculated using UM-SCC-74B with the
lowest EGFR expression levels as reference and is given as fold levels.
(B) To quantify the basal expression of phosphorylated, activated EGFR
(p-EGFR Tyr1068) flow cytometry was used. Results are given as the
median specific fluorescence intensity (MFI) of cells stained with the
specific antibody divided by the intensity of cells stained with the
isotype control antibody.
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could be sensitized to CCI-779 by the combination
whereas no further sensitization of the sensitive cell lines
was observed (Figure 4). The greatest effect was seen in
the most resistant cell line UT-SCC-23 with the highest
EGFR/p-EGFR expression. Cell viability after CCI-779
treatment was reduced from 91% to 15% after combining
CCI-779 with cetuximab. This finding suggests that pa-
tients with high EGFR/p-EGFR expressing tumors could
benefit from a combined mTORi/anti-EGFR treatment. Insupport of these results, targeting of mTOR and EGFR in
preclinical models of HNSCC has previously been shown
to result in a higher growth inhibition than treatment with
each agent alone [18,25,26]. Several studies have already
been initiated for the identification of biomarkers of
mTORi efficacy, with a focus on activation of the mTOR
and the MAPK pathway before or after treatment
(NCT00195299, CCI-779; NCT01195922, rapamycin;
both advanced disease). Moreover, EGFR expression
among others is being evaluated as biomarker for
RAD001 activity in refractory recurrent locally advanced
HNSCC (NCT01051791).
In our model of acquired cetuximab resistance, we
showed that cetuximab-resistant cell lines either did not
change their sensitivity or became more resistant to
CCI-779 (temsirolimus) compared to their sensitive
counterparts. This is in line with results from the PII
MAESTRO study in which metastatic HNC patients
with documented progression on cetuximab were treated
with either temsirolimus alone or its combination with
cetuximab [27]. This study revealed modest and short
activity of temsirolimus as single agent in this scenario.
The addition of temsirolimus to cetuximab was able to
overcome acquired cetuximab resistance in only a small
subgroup of patients (12.5%), however, these responses
were more durable than the response to the previous
cetuximab-containing regimens [27]. In our model of ac-
quired cetuximab resistance, the combined treatment of
cetuximab-resistant cells with cetuximab and CCI-779
was more effective than CCI-779 alone, supporting po-
tential clinical value of this combination. It will be im-
portant to evaluate in future studies whether expression
levels of EGFR/p-EGFR which we established here as
predictive factor for low CCI-779 sensitivity in
cetuximab-naïve HNSCC cells might also be useful as
predictive biomarker for clinical benefit of cetuximab/
temsirolimus combinations in the cetuximab-refractory
setting.
HNSCC cells with acquired resistance to cisplatin or
cetuximab show differential sensitivity to CCI-779 and
can be resensitized by combinatorial treatment.
Cisplatin and cetuximab, each of them in combination
with radiotherapy, are effective drugs in the primary
treatment of locally advanced HNSCC. In the recurrent
disease setting the tumor response to these agents is re-
duced, most likely due to selection of drug-resistant cells
during primary treatment. To evaluate the potential of
CCI-779 in the recurrent disease, we established four
models of acquired resistance to cisplatin (FaDu and
UD-SCC-4) and cetuximab (UT-SCC-9 and UM-SCC-
22B) by long-term treatment of HNSCC cell lines with
increasing concentrations of the drugs (Figure 5 A and
B). Interestingly, we observed that both cell lines with
acquired cisplatin resistance (FaDuCDDP-R and UD-SCC-
Figure 4 The combination of CCI-779 and cetuximab augments the sensitivity of cells to treatment with the mTOR inhibitor alone. All
10 cell lines were treated with increasing doses of CCI-779 (0.1-100 ng/ml) and long-term cell viability (7 days) was measured using the MTT assay.
Additionally, CCI-779 treatment was combined with cetuximab at a low dose (0.1 μg/ml), at which the drug itself showed only little effect. In
three EGFR-expressing, CCI-779 resistant cell lines the combination led to decreased cell viability (left graphs). Cell viability of sensitive cells could
not further be decreased by the combination (three representative cell lines, right graphs). Survival fractions after drug treatment were calculated
on the basis of the survival of non-treated cells.
Niehr et al. Journal of Translational Medicine  (2015) 13:106 Page 7 of 13
Figure 5 Long-term treatment of HNSCC cells with cisplatin or cetuximab selects resistant subclones. Cell lines were treated for 6-9
months with increasing doses of (A) cisplatin (FaDuCDDP-S, UD-SCC-4CDDP-S) or (B) cetuximab (UT-SCC-9CET-S, UM-SCC-22BCET-S). Doses were
elevated if the cells showed a stable growth. The resulting resistant cells (CDDP-/CET-R) as well as their sensitive parental counterparts (CDDP-/CET-S)
were used forfurther experiments.
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to their parental counterparts (FaDuCDDP-S and UD-SCC-
4CDDP-S). In contrast, cetuximab-resistant cell lines either
did not change their sensitivity (UM-SCC-22BCET-R) or be-
came more resistant to CCI-779 (UT-SCC-9CET-R) com-
pared to the parental cetuximab-sensitive cells (Figure 6).
By panel NGS analysis we detected an increased allele
frequency of a specific TP53 exon mutation (Arg248Leu)
in FaDuCDDP-R that was already present in the parental
cell line FaDuCDDP-S, indicating the selection of a pre-
existing subclone (Table 2). In the UD-SCC-4CDDP-R
cell line, the selection of subclones harboring KDR
(VEGFR2) and NSD1 mutations was observed. TP53
and KDR mutations have been associated with cisplatin
resistance [28,29] and NSD1 is known to regulate NF-
κB [30] which has also been involved in resistance tocisplatin [31]. In one of the two cetuximab-resistant
cell lines (UT-SCC-9CET-R), we observed the accumula-
tion of a subclone carrying a MET mutation which has
been shown to be involved in cetuximab resistance
[32]. The exact mechanisms of how these genetic alter-
ations are involved in CCI-779 sensitivity have to be
elucidated in future studies.
We next assessed if combinatorial treatment with
CCI-779 and cisplatin or cetuximab increased growth in-
hibition in these cell line models of acquired drug resist-
ance. Cisplatin-resistant cells with increased sensitivity
to CCI-779 could be only slightly sensitized further by
addition of cisplatin to CCI-779 only in the FaDu but
not in the UD-SCC-4 model (Figure 7). Cetuximab-
resistant cells with reduced sensitivity to CCI-779 could
be sensitized to CCI-779 by its combination with
Figure 6 Cell lines with acquired cisplatin resistance become more sensitive to CCI-779 whereas acquired cetuximab resistance leads
to decreased sensitivity to CCI-779. The sensitivity of cisplatin-resistant cells (upper panels, dashed lines) is increased when compared to their
parental counterparts (upper panels, solid lines). In contrast, cetuximab-resistant cells (lower panels, dashed lines) when compared to the parental
cells (lower panels, solid lines) remain resistant to CCI-779 (UM-SCC-22BCET-R) or become more resistant to the drug (UT-SCC-9CET-R). The survival
fractions shown were evaluated with long-term MTT assays and calculated on the basis of the survival of non-treated cells.
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mab resistance (Figure 7).
These data suggest that patients with recurrent
cisplatin-resistant tumors might benefit from mTORi
treatment. In line with our results, a clinical trial in re-
current/metastatic HNSCC addressing the efficacy of
temsirolimus after cisplatin treatment failure has shownpromising results [33]. Further drug partners in this
setting will have to be identified given the absence of
any potentiating effects of the CCI-779/cisplatin com-
bination. Treatment with the combination of cetuximab
and mTORi, but not mTORi alone could be beneficial
for patients with tumors with acquired cetuximab-
resistance. Such dual inhibition of EGFR and the
Figure 7 Addition of CCI-779 to cetuximab potentiates the inhibitory effect on cell survival in HNSCC cells with acquired resistance to
cetuximab. Cell viability of cisplatin-resistant cells (upper panels, dashed lines) can only be slightly increased in the FaDuCDDP-R model when
combining CCI-779 with cisplatin (solid lines) compared to CCI-779 single treatment. In cetuximab-resistant cells (lower panels, dashed lines), the
addition of cetuximab to CCI-779 further decreases cell viability in both models (solid lines).
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supports the need for further prospective trials in
HNSCC.
Conclusions
The results from our study demonstrating no cross-
resistance of HNSCC cells to CCI-779 and cisplatin sug-
gests that mTORi could serve as a potential treatment
option in tumors with primary resistance to cisplatin. We
identified EGFR/p-EGFR expression as potential negative
predictive biomarker for mTORi efficacy and the combin-
ation of CCI-779 and cetuximab as a therapeutic regimen
with increased growth-inhibitory potential. Our results
from the preclinical models of acquired resistance also
suggest clinical potential of mTORi in the recurrent,
cisplatin-refractory setting and its combination with cetuxi-
mab in tumors with acquired resistance to EGFR blockade.Methods
Cell lines and reagents
The HNSCC cell lines UD (University of Düsseldorf )-
SCC-4, -5, UT (University of Turku)-9, -15, -23, UM
(University of Michigan)-SCC-11B, -17B, -22B, -25, -74B,
and SCC-9 were a gift from T.K. Hoffmann (University of
Essen) and T.E. Carey (University of Michigan) [34]. FaDu
was purchased from ATCC. The identity of the cell lines
was confirmed by high-throughput SNP-based authentica-
tion (Multiplexion, Heidelberg, Germany). All cell lines
were tested for mycoplasma at monthly intervals by
RT-PCR [35]. Contaminated cultures were treated with
Mycoplasma Removal Agent (MP Biomedicals, Santa
Ana, USA) according to the manufacturer’s protocol.
Cells were cultured in Minimal Essential Medium
(MEM) supplemented with 10% heat-inactivated fetal bo-
vine serum and 1× non-essential amino acids. Acquired
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ing the cells for a period of 4-9 months in increasing con-
centrations of the respective drug. All cell culture reagents
were from GIBCO (life technologies, Carlsbad, CA, US).
Cell cultures were incubated at 37°C and 5% CO2 in a
humidified atmosphere. CCI-779 was provided by Pfizer
(Berlin, Germany) and diluted in dimethylsulfoxide
(DMSO) to a stock of 1 mg/ml. Cisplatin was purchased
from Sigma-Aldrich (Munich, Germany) and cetuximab
was provided by Merck (Darmstadt, Germany). Working
solutions were freshly prepared from the stock solution
by dilution in cell culture medium on the day of the
experiment.MTT viability assays
Cells were seeded into 96-well plates at a density of 250-
300 cells/well. Twenty-four hours after seeding, cells were
treated with CCI-779, cisplatin, cetuximab, or the combin-
ation. Cells were then incubated for 72 h (short-term) or
7 days (long-term). At the end of the experiments 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
reagent (MTT) was added to the cells and after one
hour incubation formazan complexes were dissolved in
DMSO and absorbance measured with a spectrophotom-
eter. Survival fractions for given treatments were calculated
on the basis of survival of untreated cells. Each sample was
done in sextuplets and at least three independent experi-
ments were carried out. From the dose-effect curves the
IC50 values for cisplatin were calculated.
Immunoblotting analysis
Expression levels of phosphorylated and total proteins in
cell lysates of HNSCC cell lines, either untreated or
treated with 100 ng/ml CCI-779 were assessed by standard
Western blot analysis. Briefly, cells were harvested by
scraping in RIPA buffer. Standard SDS–polyacrylamide gel
electrophoresis was performed using 40 μg of total protein
per sample, followed by transfer to PVDF membranes
(Millipore, Billerica, MA, US). For detection, the following
antibodies were used: p-EGFR Tyr1068 (#2234), p-Erk
Thr202/Tyr204 (clone D13.14.4E), Erk (clone 137 F5),
p-S6 Ser235/236 (clone D57.2.2E), S6 (clone 5G10), p-S6K
Thr389 (clone 108D2), S6K (clone 49D7) and GAPDH
(clone 14C10), all from Cell Signaling Technology
(Danvers, MA, US). The antibody against p53 (clone DO-1)
was purchased from Santa Cruz (Santa Cruz, CA, US)
and anti-EGFR (clone 13) from BD Biosciences (Franklin
Lakes, NJ, US). Secondary antibodies included peroxidase-
conjugated goat anti-mouse and goat anti-rabbit both
from Jackson ImmunoResearch Laboratories (West Grove,
PA, US). The immunoreactivity was detected using the
Pierce ECL Plus Western Blotting Substrate (Thermo
Scientific, Waltham, MA, US).Flow cytometry
Cells were harvested by trypsinization and fixed in fix-
ation buffer (Nordic MUbio, Susteren, Netherlands).
Cells were incubated with primary and secondary anti-
bodies in permeabilization buffer (Nordic MUbio) for
20 min each and were subsequently analyzed using the
FACSCanto II cytometer and the FACSDiva Software v6
(BD Biosciences). The following antibodies were used
for staining: rabbit anti-p-EGFR Tyr1068 (cell signaling),
rabbit IgG isotype control and goat anti-rabbit FITC
(Life Technologies, Darmstadt, Germany). Median specific
staining intensity (MFI) was calculated as ratio of the
fluorescence intensity of cells stained with the specific
antibody and the isotype control.Sequencing analysis
RNA was isolated and TP53 transcript expression analysis
as well as Sanger sequencing was performed (Source Bio-
Science, Berlin, Germany). For the panel-based next gen-
eration sequencing experiments, library preparation and
semiconductor sequencing was performed as follows.
Using the multiplex PCR based Ion Torrent approach as
described previously [36,37], for this study an in-house
gene panel for 45 HNSCC-related cancer genes was de-
signed (see Additional file 1) using the COSMIC database
[38] as well as two publications on exome sequencing data
of HNSCC tumor material [39,40]. DNA was extracted
from all of the cell lines with the Invisorb Spin Tissue
Mini Kit (Stratec, Birkenfeld, Germany). Amplicon library
preparation was performed using approximately 10 ng of
DNA as advised by the manufacturer. Briefly, the DNA
was mixed with the primer pool, containing all primers for
generating the 224 amplicons and the AmpliSeq HiFi
Master Mix, and transferred to a PCR cycler (BioRad,
Munich, Germany). PCR cycling conditions were as fol-
lows: Initial denaturation: 99°C for 2 min, cycling: 21 cycles
at 99°C for 15 sec and 60°C for 4 min. Subsequent to the
PCR reaction, primer end sequences were partially
digested using the FuPa reagent as instructed, followed by
the ligation of barcoded sequencing adapters (Ion Xpress
Barcode Adapters, Life Technologies). The final library
was purified using AMPure XP magnetic beads (Beckman
Coulter, Krefeld, Germany) and quantified using qPCR
(Ion Library Quantitation Kit, Life Technologies) on a Ste-
pOnePlus Instrument (Life Technologies). The individual
libraries were diluted to a final concentration of 100pM
and eight to ten libraries were pooled and processed to
library amplification on Ion Spheres using the Ion One-
Touch 2 instrumentation with the 200 bp chemistry. Un-
enriched libraries were quality-controlled using Ion Sphere
quality control measurement on a QuBit instrument. After
library enrichment (Ion OneTouch ES), the library was
processed for sequencing using the Ion Torrent 200 bp
Niehr et al. Journal of Translational Medicine  (2015) 13:106 Page 12 of 13sequencing chemistry and the barcoded eight to ten librar-
ies were loaded onto a single 318 chip.
Raw data analysis was performed using Ion Torrent
Software Suite (Version 3.6 and 4.0). The reads were
aligned to the human reference sequence build 38 (hg19)
using the TMAP aligner implemented in the Torrent Suite
software. Detection of single base pair variants and
insertion-deletion polymorphisms (InDels) compared to
the human reference sequence was performed using either
Ion Torrent Variant Caller (3.6 and 4.0). Detection
thresholds for SNPs and InDels were set at an allele fre-
quency of 5%. Variants were annotated and filtered against
the dbSNP and COSMIC databases and screened for pos-
sible splice site effects using the CLC genomics Suite 6
(CLCbio, Aarhus, Denmark). Copy number variations
were determined using the coverage analysis plug-in of
the Torrent Suite software.
Transcript expression analysis
Basal and irradiation-induced p21 expression levels, as
read-out for p53 transcriptional activity in HNSCC cell
lines, as well as basal EGFR levels were determined by
quantitative reverse-transcriptase polymerase chain reac-
tion (qRT-PCR). Total cellular RNA extraction was per-
formed using the High Pure RNA Isolation Kit (Roche,
Basel, Switzerland). Synthesis of cDNA was done with the
Omniscript Reverse Transcription kit (QIAGEN, Hamburg,
Germany), according to the supplied protocol, using ran-
dom hexamers and oligo dT15 primers (Roche) and 2 μg of
total RNA. The quality of RNA was checked by GAPDH
PCR and only samples positive for GAPDH transcripts
were used for analysis. Real-time-PCR was performed in a
reaction volume of 20 μl containing 2 μl cDNA, Light
Cycler TaqMan Master (Roche), primers and probes for
p21, EGFR and the housekeeping gene porphobilinogen
deaminase (PBGD) in concentrations recommended by the
manufacturer (Real Time Ready Assays, Roche). PCR cyc-
ling was performed using a Light Cycler (Roche). Relative
quantification of p21 and EGFR expression was done by
normalization to the expression levels of PBGD.
Statistical analysis
All statistical analyses were performed using SPSS v.20.0
(IBM Corp., Armonk, NY, USA) software. The signifi-
cance of differences in the cell survival fraction after
treatment with 100 ng/ml temsirolimus of cell lines
exhibiting diverse characteristics regarding TP53 was de-
termined using the independent-samples t-test. The level
of significance was set at p < 0.05.Additional file
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